A method of macular disease treatment (500) may include introducing nanocapsules into a body of a patient (502). The nanocapsules may be introduced such that the nanocapsules circulate through at least a portion of a body of the patient. A therapeutic substance and a colorant may be encapsulated into the nanocapsules. After a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include emitting a pulsed laser radiation through a pupil of the eye (504). Additionally, after a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include heating the portion of the nanocapsules present in the eye (506) such that at least a portion of the nanocapsules transfer phase and release the therapeutic substance.

The subject invention provides materials and methods for intracellular deliver of molecules and/or therapeutic agents. The subject invention also provides methods for synthesizing polymeric systems and nanomaterials that enhance or assist the passage of molecules and/or therapeutic agents across biological membranes. The compound, polymer or nanoparticle of the subject invention comprises a modified guanidine moiety in a plurality of repeating units of a polymer or on the surface of a nanoparticle where the guanidine moiety comprises, for example, a carbamoyl or thiourea modification. The polymer or nanoparticle can be used in a cancer treatment formulation.

A process for the preparation of a nanoparticulate active ingredient comprises the steps of: a) providing a solvent, a pharmaceutical active ingredient dissolved in the solvent, a liquid antisolvent and a stabilizer which is dissolved in the solvent or in the antisolvent and wherein the antisolvent is miscible in the solvent; b) mixing the solvent, the active ingredient, the antisolvent and the stabilizer in a micromixer, thereby obtaining a suspension comprising a precipitate of the active ingredient, the solvent and the antisolvent. The active ingredient precipitate is present in the form of nanoparticles having an average particle size of ≥10 nm to ≤999 nm and a particle size distribution, determined by dynamic light scattering (DLS) according to ISO 22412:2017, having a polydispersity index of ≤0.2.

A process for producing a pharmaceutical formulation comprises the steps of: A) suspending a pharmaceutical active substance in an aqueous solution of a polymer; B) drying the mixture obtained in step A); wherein in step A) the pharmaceutical active substance is present in the form of particles having a d.sub.90 value in the particle size distribution of ≤1 μm and before step B) the pharmaceutical active substance is further contacted with an ionic surfactant.

Mucus penetrating nanoparticles for inducing, increasing, or enhancing an immune response typically include core of a blend of a biodegradable hydrophobic polymer and a hydrophilic polymer, wherein ≥50% of the biodegradable polymer is conjugated to the hydrophilic polymer, and the hydrophilic polymers forms a coating on the particle. The particles encapsulate a cargo, typically an antigen, adjuvant or other immunomodulator, or a nucleic acid encoding the antigen, or combination thereof. Pharmaceutical compositions including an effective amount of particles to induce an immune response in a subject in need thereof are also provided. Methods of inducing an immune response are also provided, and typically include administering to a subject, preferably via the respiratory tract, the pharmaceutical composition. In some embodiments, the subject has cancer or an infection of the lung.

The invention provides methods of making microparticle and nanoparticle ocular implants from a compositions comprising: 99 to 60% (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent.

The present invention is a new controlled drug system that can be used for targeting non-invasive neuromodulation enabled by focused ultrasound gated release of one or more small molecule neuromodulatory agents.

This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection. In an embodiment, this disclosure provides a particle heater comprising a carrier admixed with a material that interacts with an exogenous source; wherein the material absorbs and converts the energy from the exogenous source into heat, then the heat travels outside the particle heater to induce localized hyperthermia at a temperature sufficient to selectively kill unwanted cells, and further wherein the particle heater structure is constructed such that it passes the Extractable Cytotoxicity Test.

Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density.

This disclosure relates to nanoparticles for preventing, treating and reversing atherosclerosis.